Accordingly, simvastatin impairs binding and entry of SARS-CoV-2 in Calu-3, possibly due to the dislodgment of ACE2 from lipid nanodomains caused by the drug and despite the increase in ACE2 expression that both simvastatin and infection provoke in these cells (7). The gene discussed is ACE2; the disease is infection.